Deformed macrophages, their preparation methods and applications, and macrophage extracellular vesicles and their applications
By processing and culturing macrophages through microchannels to obtain deformed macrophages and extracellular vesicles, the problem of functional decline in senescent macrophages has been solved, achieving therapeutic effects in tumor treatment and aging-related diseases.
Patent Information
- Application Number
- CN202611235476.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-14
- Publication Date
- 2026-11-17
AI Technical Summary
Current technologies cannot effectively reverse the functional decline of aging macrophages, leading to problems such as decreased phagocytic capacity, increased basic inflammatory signals, and epigenetic remodeling.
By microchannel treatment of macrophages to achieve transient nuclear deformation, deformed macrophages are prepared. Extracellular vesicles of macrophages are obtained through culture, which enhance their metabolic function, autophagy level, secretion and migration of inflammatory factors, and reduce ROS level.
Deformed macrophages significantly enhance cell performance and can be used for tumor treatment. Macrophage extracellular vesicles are used for breast cancer treatment, ovarian aging treatment, and cognitive function improvement.
Smart Images

Figure CN123107928A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of treatment technology for aging-related diseases, and more specifically, to a deformed macrophage, its preparation method and application, and macrophage extracellular vesicles and their applications. Background Technology
[0002] As we age, the immune function of macrophages gradually declines, mainly manifested as decreased phagocytic capacity, increased basal inflammatory signals, and epigenetic remodeling. Current technologies can intervene in age-related diseases using anti-inflammatory drugs, senescent cell scavengers, and metabolic regulators, but these methods cannot reverse the function of aging macrophages. Summary of the Invention
[0003] This application provides a deformable macrophage, its preparation method and application, as well as macrophage extracellular vesicles and their applications. The deformable macrophage can be used for tumor treatment, and the macrophage extracellular vesicles can be used for cancer treatment.
[0004] This invention is implemented as follows:
[0005] In a first aspect, this application provides a deformed macrophage for treating tumors, wherein the deformed macrophage is obtained by nuclear deformation treatment of macrophages through microchannels for 190-210 ns.
[0006] Secondly, this application provides a method for preparing the above-mentioned deformed macrophages for treating tumors, comprising the following steps: injecting a macrophage suspension into the microchannel at a flow rate of 500-700 μL / min to perform nuclear deformation treatment, causing the macrophages to undergo transient deformation, and then culturing them.
[0007] Thirdly, this application provides the use of deformed macrophages prepared by the method of the first aspect or the method of the second aspect in the preparation of drugs for treating tumors.
[0008] Fourthly, this application provides a macrophage extracellular vesicle, which is obtained by culturing the deformed macrophages of the first aspect or the deformed macrophages prepared by the preparation method of the second aspect in a serum-free culture medium or a complete culture medium containing fetal bovine serum without extracellular vesicles in a 37°C, 5% CO2 incubator for 24 to 72 hours, and then collecting the culture supernatant.
[0009] Fifthly, this application provides the use of macrophage extracellular vesicles in the preparation of a drug for treating cancer, specifically breast cancer.
[0010] Sixthly, this application provides the use of macrophage extracellular vesicles in the preparation of a drug for treating ovarian aging, as described in the fourth aspect.
[0011] In a seventh aspect, this application provides the use of macrophage extracellular vesicles in the preparation of a drug for improving cognitive function, as described in the fourth aspect.
[0012] The beneficial effects of this application include at least the following:
[0013] Senescent macrophages, after undergoing transient nuclear deformation treatment in microchannels, yield deformed macrophages. These deformed macrophages exhibit enhanced metabolic function, autophagy levels, inflammatory cytokine secretion, phagocytic capacity, and migration ability, while also showing decreased ROS levels and significantly improved cell performance. They can be used for tumor treatment, reducing tumor volume. Extracellular vesicles secreted by deformed macrophages can be used to treat breast cancer, as well as ovarian aging and cognitive function. Attached Figure Description
[0014] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained from these drawings without creative effort.
[0015] Figure 1 This is a graph showing the cell survival / death ratio in a specific embodiment of this application;
[0016] Figure 2 This is a graph showing the results of cell DNA damage rate in a specific embodiment of this application;
[0017] Figure 3 This is a graph showing the results of cell activity in a specific embodiment of this application;
[0018] Figure 4 This is a graph showing the ATP production results of cells in a specific embodiment of this application;
[0019] Figure 5 This is a diagram of the ROS levels of cells in a specific embodiment of this application;
[0020] Figure 6 This is a diagram of the autophagy level of cells in a specific embodiment of this application;
[0021] Figure 7 This is a diagram showing the levels of different inflammatory cytokines secreted by cells in a specific embodiment of this application;
[0022] Figure 8 This is a graph showing the cell migration speed results in a specific embodiment of this application;
[0023] Figure 9 This is a graph showing the changes in ATP and ROS levels in a specific embodiment of this application;
[0024] Figure 10 This is a graph showing the total SRC and pSRC levels of cells in a specific embodiment of this application;
[0025] Figure 11 This is a Western blot diagram of the expression levels of nucleoplasmic YAP and pYAP in the specific embodiments of this application;
[0026] Figure 12 This is an image showing the immunofluorescence detection results of nucleoplasmic YAP and pYAP in a specific embodiment of this application;
[0027] Figure 13 This is a diagram showing the TET1 level results in a specific embodiment of this application;
[0028] Figure 14 This is a graph showing the 5mC level variation in a specific embodiment of this application;
[0029] Figure 15 This is a graph showing the cytokine release levels in a specific embodiment of this application;
[0030] Figure 16 This is a graph showing the expression levels of genes related to reversing aging in a specific embodiment of this application;
[0031] Figure 17 This is a diagram showing the cellular DNA methylation results in a specific embodiment of this application;
[0032] Figure 18 This is the result of the H3K27me3 expression level in deformed macrophages in the specific embodiments of this application;
[0033] Figure 19 This is the result of H3K9me3 expression level in deformed macrophages in the specific embodiments of this application;
[0034] Figure 20 This is a graph showing the 5mC expression level of amorphous macrophages in a specific embodiment of this application;
[0035] Figure 21 This describes the tumor status of breast cancer mice treated with and without injection of deformed macrophages in Example 1 of this application.
[0036] Figure 22 This describes the survival rates of breast cancer mice treated with and without injection of deformed macrophages in Example 1 of this application.
[0037] Figure 23 This describes the changes in tumor diameter in mice treated with and without macrophage extracellular vesicles in Example 2 of this application.
[0038] Figure 24This describes the expression of tumor proliferation markers in mice treated with and without macrophage extracellular vesicles in Example 2 of this application.
[0039] Figure 25 This refers to the birthing time, number of pups, and ovarian weight of mice treated with and without macrophage extracellular vesicles in Example 2 of this application.
[0040] Figure 26 This describes the cold stimulation response of mice treated with macrophage extracellular vesicles and those not treated in Example 2 of this application.
[0041] Figure 27 This describes the time spent in the central region of mice treated with macrophage extracellular vesicles and mice that were not injected, as shown in Example 2 of this application. Detailed Implementation
[0042] The embodiments of this application will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of this application. Unless otherwise specified in the examples, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.
[0043] In a first aspect, this application provides deformed macrophages for treating tumors, which are obtained by nuclear deformation treatment of macrophages in microchannels for 190-210 ns. Exemplarily, the microchannels have a height of 15 μm and a width of 5 μm.
[0044] Secondly, the aforementioned deformed macrophages for tumor treatment are prepared using the following steps: injecting a macrophage suspension into a microchannel at a flow rate of 500-700 μL / min to perform nuclear deformation treatment, causing the macrophages to undergo transient deformation, followed by culture. Exemplarily, the microchannel is provided by a microfluidic chip. That is, after the macrophage suspension is injected into the microchannel at a flow rate of 500-700 μL / min, it remains in the microchannel for 190 ns-200 ns, during which time the microchannel exerts pressure on the macrophages. Optionally, the nuclear deformation treatment time is any one or any combination of 190 ns, 193 ns, 195 ns, 198 ns, 200 ns, 203 ns, 205 ns, 208 ns, and 210 ns.
[0045] In one embodiment, the microfluidic chip uses polydimethylsiloxane (PDMS) as the chip material and glass as the substrate. The microfluidic chip is fabricated using soft photolithography, with the specific steps as follows:
[0046] (1) Mold preparation: Using a four-inch silicon wafer, SU-8 2015 photoresist pattern with a thickness of 15 micrometers was prepared by photolithography.
[0047] (2) PDMS mixing: Mix PDMS matrix and curing agent at a weight ratio of 10:1 and degas in a vacuum chamber for 1 hour;
[0048] (3) Curing: Curing at 65°C for 4 hours;
[0049] (4) Plasma treatment: oxygen plasma treatment for 30 seconds to enhance hydrophilicity;
[0050] (5) Bonding: Bond the PDMS layer to the glass substrate and bake at 65°C for 10 minutes to enhance the bonding strength.
[0051] The microfluidic chip features multiple parallel microchannels. To compare the effects of different microchannel sizes on the transient nucleus morphology of macrophages, the inventors designed microchannels with a uniform height of 15 μm and widths of 3 μm, 5 μm, 7 μm, and 200 μm. The microfluidic chip is equipped with an inlet and an outlet for connecting to an injection pump and a cell collection tube, respectively. A suspension of aged macrophages was injected into the microchannels at a flow rate of 500–700 μL / min through the different microchannels.
[0052] Before injecting the macrophage suspension into the microchannel, the cell diameter, nuclear diameter, and Young's modulus of the macrophages were measured. The average macrophage diameter ranged from 10.44 to 11.12 μm, the average nuclear diameter ranged from 7.100 to 7.534 μm, and the Young's modulus ranged from 1067 to 1313 kPa. After passing aged macrophages through the microchannel, cell viability, cell activity, and DNA damage were assessed. The results showed that compared to the 200 μm microchannel (control group), the 5 μm and 7 μm channels resulted in a cell death rate of less than 0.5%, slightly higher cell activity, and a DNA damage rate of less than 1%; while the 3 μm channel resulted in a 5% cell death rate, cell activity of less than 50%, and DNA damage approaching 10%. Therefore, in this embodiment, a microchannel with a height of 15 μm and a width of 5 μm was selected for transient nuclear deformation treatment of macrophages.
[0053] Specifically, the macrophages used were bone marrow macrophages (BMDM) obtained from 70-week-old female mice. The specific steps are as follows:
[0054] (1) Female C57BL / 6 or BALB / c mice aged 70 weeks were euthanized by dislocation;
[0055] (2) Aseptically separate the femur and tibia to expose the medullary cavity;
[0056] (3) Flush the bone marrow cavity with RPMI 1640 medium (containing 10% FBS and 1% penicillin-streptomycin);
[0057] (4) Culture for 7 days to induce differentiation into macrophages;
[0058] During the injection of macrophage suspension at a rate of 500–700 μL / min into the microchannels, the macrophages undergo transient deformation as they pass through the narrow channels, and their nuclei are simultaneously subjected to mechanical compression. The microchannels have a uniform height of 15 μm and widths of 3 μm, 5 μm, 7 μm, and 200 μm (corresponding to ctrl in the figure). The deformed macrophages that have passed through the microchannels are collected and cultured normally at 37°C and 5% CO2. Functional assessments are performed at 6, 24, and 48 hours post-treatment, including safety and functional recovery tests.
[0059] I. Safety testing was performed on amorphous macrophages 24 hours after culture.
[0060] (1) Cell membrane integrity: The trypan blue exclusion assay was used for detection. The mortality rate of deformed macrophages obtained by transient nuclear deformation through microchannels with a width of 5 μm and 7 μm was <0.5%, while the mortality rate of deformed macrophages obtained by transient nuclear deformation through microchannels with a width of 3 μm was much greater than 0.5% (e.g. Figure 1 (As shown).
[0061] (2) DNA damage: γ-H2AX immunofluorescence was used for detection. The DNA damage rate of aberrant macrophages obtained through transient nuclear deformation via microchannels with widths of 5 μm and 7 μm was <1%; while the DNA damage rate of aberrant macrophages obtained through transient nuclear deformation via microchannels with widths of 3 μm was much greater than 1% (e.g., ...). Figure 2 (As shown).
[0062] (3) Cell viability: The MTS assay was used to detect the cell viability of deformed macrophages obtained by transient nuclear deformation through microchannels with widths of 5 μm and 7 μm was higher than that of the control group (treated with microchannels with widths of 200 μm), while the cell viability of deformed macrophages obtained by transient nuclear deformation through microchannels with widths of 3 μm was significantly lower than that of the control group (e.g., Figure 3 (As shown).
[0063] II. Functional recovery was assessed after 24 hours of culture of amorphous macrophages. In the figure, Sqz, Young, and old represent amorphous macrophages obtained by transient nuclear deformation through a 5μm wide microchannel, 4-week-old mouse cells without nuclear deformation treatment, and 70-week-old mouse cells without nuclear deformation treatment, respectively.
[0064] (1) Metabolic function: The amount of ATP (adenosine triphosphate) produced by deformed macrophages through transient nuclear deformation via a 5 μm wide microchannel was more than 2 times higher than that produced by untreated macrophages, approaching the level of young cells (e.g., Figure 4 (As shown).
[0065] (2) ROS level: The ROS (reactive oxygen species) level of deformed macrophages obtained by transient nuclear deformation through a 5μm wide microchannel was reduced to 60%, close to the level of young cells (e.g., Figure 5 (As shown).
[0066] (3) Autophagy level: Compared with untreated macrophages, the autophagy level of deformed macrophages obtained by transient nuclear deformation through a 5 μm wide microchannel was increased by 2 times, reaching the level of young cells (e.g., Figure 6 (As shown).
[0067] (4) Secretion of inflammatory factors: Compared with untreated macrophages, deformed macrophages obtained by transient nuclear deformation through a 5 μm wide microchannel showed a significant increase in 31 different inflammatory cytokines, with the expression levels of some cytokines even exceeding those of young cells (e.g., Figure 7 (As shown).
[0068] (5) Migration ability: Compared with untreated macrophages, the migration speed of deformed macrophages obtained by transient nuclear deformation through a 5μm wide microchannel was increased by about 2 times, comparable to that of young cells (e.g., Figure 8 (As shown).
[0069] III. Transient nuclear deformation activates mitochondrial and endoplasmic reticulum function
[0070] (1) Macrophages were pretreated with the mitochondrial function inhibitor MFI8 (20 µM) and the endoplasmic reticulum protein folding inhibitor DTT (500 µM) for 24 h. Then, macrophage suspension was injected at a rate of 500–700 μL / min into microchannels 5 μm wide and 15 μm high for transient nuclear deformation treatment, followed by 6 h of culture. The resulting deformed macrophages were then subjected to whole-genome sequencing. Whole-genome sequencing (RNA-seq) showed significant enrichment of mitochondrial tissue, endoplasmic reticulum stress response, and mitochondrial membrane potential regulation pathways. Specifically, the results (e.g.) Figure 9 As shown in the image:
[0071] 1) MFI8 treatment eliminated the squeeze (Sqz)-induced increase in ATP and blocked the decrease in ROS;
[0072] 2) DTT treatment had no effect on ATP or ROS levels, indicating that endoplasmic reticulum folding functions through pathways parallel to or downstream of mitochondrial energy metabolism.
[0073] (2) SRC (proto-oncogene tyrosine-protein kinase Src) kinase was used to activate amorphous macrophages.
[0074] RNA-seq analysis showed that after transient nuclear deformation treatment by injecting macrophage suspension at a rate of 500–700 μL / min into microchannels with a width of 5 μm and a height of 15 μm, followed by 6 h of culture, the total SRC and phosphorylated SRC (pSRC) of macrophages were approximately twice that of old macrophages (Sqz BMDM). Pretreatment of macrophages with the mitochondrial function inhibitor MFI8 (20 µM) and the endoplasmic reticulum protein folding inhibitor DTT (500 µM) for 24 h, followed by transient nuclear deformation treatment and 6 h of culture, did not upregulate the total SRC and pSRC. This indicates that the increase in SRC protein levels and the upregulation of phosphorylated SRC levels exert their effects through mitochondrial energy metabolism and downstream pathways of endoplasmic reticulum folding (e.g., Figure 10 (As shown).
[0075] (3) YAP (Yes-associated protein) nuclear transport
[0076] Experimental results (such as) Figure 11 As shown in the figure, pSRC promotes YAP nuclear translocation. After transient nuclear deformation treatment by injecting macrophage suspension at a rate of 500–700 μL / min into microchannels with a width of 5 μm and a height of 15 μm, followed by 6 h of culture, nuclear YAP and nuclear pYAP expression increased threefold, while cytoplasmic YAP and pYAP levels decreased. However, after pretreatment of macrophages with a pSRC protein inhibitor for 24 h followed by transient nuclear deformation treatment and 6 h of culture, nuclear YAP and nuclear pYAP expression did not increase, and cytoplasmic YAP and pYAP levels did not decrease, indicating that the increased YAP nuclear translocation occurs through a downstream pathway of upregulated phosphorylated SRC levels. Immunofluorescence assays also confirmed this process (e.g., Figure 12 (As shown).
[0077] (4) TET1-mediated DNA demethylation
[0078] Macrophage suspension was injected at a rate of 500–700 μL / min into microchannels with a width of 5 μm and a height of 15 μm for transient nuclear deformation treatment. After 24 hours of culture, the 5mC level was significantly reduced. TET1 (Ten-Eleven Translocation protein 1) levels were upregulated by 60% after 24 hours of treatment. Pretreatment with a TET1 inhibitor (30 µM) for 24 hours followed by microfluidic processing showed the following results:
[0079] 1) TET1 levels will no longer be increased (e.g.) Figure 13 As shown); 2) The 5mC level change is similar to the TET1 level trend (e.g. Figure 14 As shown); 3) Cytokine release is inhibited (e.g. Figure 15 As shown); 4) Downregulation of the expression of aging-related genes (such as Mturn, Cnbd2, Mest) (as shown); Figure 16 (As shown).
[0080] (5) Epigenetic remodeling effect
[0081] (1) DNA methylation: The X chromosome of amorphous macrophages obtained by transient nuclear deformation through a 5 μm wide microchannel showed the most significant demethylation changes (e.g. Figure 17 (As shown).
[0082] (2) Histone methylation: The levels of H3K27me3 and H3K9me3 in deformed macrophages obtained by transient nuclear deformation through a 5 μm wide microchannel were significantly reduced, reaching the level of young cells (e.g., Figure 18 and Figure 19 (As shown).
[0083] (3) 5mc level: The 5mc level of deformed macrophages obtained by transient nuclear deformation through a 5μm wide microchannel was reduced by about 2 times, which is lower than that of young cells; the chromatin density was reduced by about 1.1 times (e.g. Figure 20 (As shown).
[0084] The following examples provide a more detailed description of the deformed macrophages, their preparation method, their applications, and macrophage extracellular vesicles and their applications.
[0085] Thirdly, this application provides the use of deformed macrophages prepared by the method of the first aspect or the method of the second aspect in the preparation of a medicament for treating tumors. Exemplarily, the tumor is a breast tumor.
[0086] Fourthly, this application provides a macrophage extracellular vesicle, which is obtained by culturing deformed macrophages prepared by the method of the first aspect or the method of the second aspect in a serum-free culture medium or a complete culture medium containing fetal bovine serum without extracellular vesicles in a 37°C, 5% CO2 incubator for 24 to 72 hours, and then collecting the culture supernatant.
[0087] Among them, macrophage extracellular vesicles can be used in the preparation of drugs for treating cancer (such as breast cancer), drugs for treating ovarian aging, or drugs for improving cognitive function.
[0088] Example 1
[0089] This embodiment provides a deformed macrophage for treating tumors, the preparation method of which includes the following steps:
[0090] Bone marrow macrophages (BMDM) obtained from 70-week-old female mice were injected in a microfluidic chip into microchannels 15 μm high and 5 μm wide at a flow rate of 500–700 μL / min, causing transient deformation of the macrophages. The deformed macrophages that passed through the microchannels were collected and cultured normally at 37°C and 5% CO2 for 24 h.
[0091] Cultured amorphous macrophages, PBS-buffered macrophages (control group), and untreated macrophages were locally injected into the tumor sites of breast cancer mice. Samples were collected 7 days later. Figure 21 and Figure 22 The results showed that the tumor volume shrank to 20% of the control group, significantly better than the untreated elderly macrophage treatment group (tumor volume shrank to 70%), and the survival rate was significantly improved. This demonstrates that the deformed macrophages of this embodiment can shrink breast cancer tumors and can be used for the treatment of breast cancer. Figure 21 In this context, Sham refers to healthy mice, Ctrl refers to breast cancer mice injected with PBS buffer, Old refers to breast cancer mice injected with macrophages that have not been treated with microchannels, and Sqz refers to breast cancer mice injected with deformed macrophages from Example 1.
[0092] Example 2
[0093] The deformed macrophages collected in Example 1 through microchannels were cultured in a serum-free incubator at 37°C and 5% CO2 for 24-72 hours, and the culture supernatant was collected to obtain macrophage extracellular vesicles.
[0094] (1) Macrophage extracellular vesicles were injected into aged female mice via the tail vein, followed by local injection of breast cancer cells to induce breast cancer. Figure 23 and Figure 24The results showed that, compared with the group that did not receive macrophage extracellular vesicle injection, the tumor growth rate and the expression of tumor proliferation markers were significantly reduced in the mice injected with macrophage extracellular vesicle injection.
[0095] (2) Macrophage extracellular vesicles were injected bilaterally into aged female mice. Figure 25 The results showed that the litter size of mice without macrophage extracellular vesicles was 53.4 days, while that of mice injected with macrophage extracellular vesicles was 31 days. The litter size of mice injected with macrophage extracellular vesicles was significantly shorter, and the litter size increased from 2.6 to 7.8 pups, with ovarian weight doubling. This indicates that macrophage extracellular vesicles help enhance ovarian function.
[0096] (3) Aged female mice were given aerosolized macrophage extracellular vesicles. From Figure 26 The results showed that the cold stimulus response time of mice without macrophage extracellular vesicles was 7.06 seconds, while that of mice injected with macrophage extracellular vesicles was 3.07 seconds, indicating a significant reduction in cold stimulus response time. The time spent in the central region of the open field by mice injected with macrophage extracellular vesicles returned to youthful levels. Figure 27 (As shown in the image). This demonstrates that extracellular vesicles of macrophages help improve cognitive function in aged mice.
[0097] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the invention by those skilled in the art. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the invention should be included within the scope of protection of the invention.
Claims
1. A deformed macrophage for treating tumors, characterized in that, The deformed macrophages were obtained by treating macrophages with nuclear deformation via microchannels for 190-210 ns.
2. The deformed macrophages for treating tumors according to claim 1, characterized in that, The microchannel is rectangular, with a height of 15μm and a width of 5μm.
3. A method for preparing deformed macrophages for treating tumors as described in claim 1, characterized in that, Includes the following steps: Macrophage suspension was injected into the microchannel at a flow rate of 500-700 μL / min to induce nuclear deformation, causing the macrophages to undergo transient deformation, and then cultured.
4. The method for preparing deformed macrophages for treating tumors according to claim 3, characterized in that, The microchannels are provided by a microfluidic chip.
5. The use of deformed macrophages as described in any one of claims 1 to 2 or deformed macrophages prepared by the preparation method as described in any one of claims 3 to 4 in the preparation of drugs for treating tumors.
6. The application according to claim 5, characterized in that, The tumor is a breast tumor.
7. A macrophage extracellular vesicle, characterized in that, It is obtained by culturing deformed macrophages as described in any one of claims 1 to 2 or deformed macrophages prepared by the preparation method described in any one of claims 3 to 4 in serum-free culture medium or complete culture medium with fetal bovine serum removed from outer vesicles in a 37°C, 5% CO2 incubator for 24 to 72 hours, and then collecting the culture supernatant.
8. The use of the macrophage extracellular vesicles as described in claim 7 in the preparation of a medicament for treating cancer, characterized in that, The cancer in question is breast cancer.
9. The use of the macrophage extracellular vesicle as described in claim 7 in the preparation of a medicament for treating ovarian aging.
10. The use of the macrophage extracellular vesicle as described in claim 7 in the preparation of a medicament for improving cognitive function.
